Galapagos NV Sponsored ADR GLPG 深 沪
等待开盘 03-31 09:30:00 美东时间
28.84
-0.090
-0.31%
华盛通- 最 高29.09
- 今 开29.08
- 成交量 13.46万股
- 最 低 28.70
- 昨 收 28.93
- 总市值 19.00亿
- 52周最高 37.78
- 市盈率 静 5.25
- 换手率 0.20%
- 52周最低 22.591
- 委 比 -66.67%
- 总股本 6589.71万
- 历史最高 274.03
- 量 比 0.41
- 振 幅 1.35%
- 历史最低 13.023
- 每 手 1
- 风险率 2.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reported Earlier, Galapagos Eyes Strategic Collaboration With Gilead On T Cell Engager Program After $1.675B Ouro Acquisition With Additional $500M Milestone Payments
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro MedicinesNew partnership structure would achieve meaningfully improved financial terms and flexibility for
03-24 15:39
Galapagos NV Board Creates 1.75M Subscription Rights Under New Subscription Right Plan
Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription right plan.On March 6, 2026, the
03-07 05:06
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $33
RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from $32 to $33.
02-25 23:49
Earnings Breakdown: Galapagos Q4
Galapagos (NASDAQ:GLPG) announced its Q4 earnings on Monday, February 23, 2026 ...
02-24 05:52
Galapagos Q4 EPS $13.82 increased from $0.30, Sales $1.049B increased from $80.575M
Galapagos (NASDAQ:GLPG) reported quarterly earnings of $13.82 per share. This is a 4506 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $1.049
02-24 05:50
Earnings Scheduled For February 23, 2026
Companies Reporting Before The Bell • Domino's Pizza (NASDAQ:DPZ) is likely to ...
02-23 19:11
Galapagos To Wind Down Cell Therapy Business After Works Council Approval, Impacting ~365 Jobs And Closing Multiple Global Sites
Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to
01-06 05:02
Galapagos' GLPG3667 Meets Primary Endpoint In Dermatomyositis Study, Shows Mixed Results In Lupus Phase 3-Enabling Trials; Galapagos Will Evaluate All Strategic Alternatives, Including Resumption Of Its Partnering Process, To Accelerate Further Development Of GLPG3667 In Dermatomyositis And Potentially Other Severe Auto-Immune Indications
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placeboIn the systemic
2025-12-19 05:02
Galapagos Shares Updated ATALANTA-1 Results At ASH 2025 Showing High Response Rates And Durable Responses With GLPG5101 In MCL
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day
2025-12-08 15:42
